HLB bioStep Co.,Ltd. (KOSDAQ:278650)

HLB bioStep Statistics

Total Valuation

HLB bioStep has a market cap or net worth of KRW 135.07 billion. The enterprise value is 137.38 billion.

Market Cap	135.07B
Enterprise Value	137.38B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

HLB bioStep has 84.47 million shares outstanding. The number of shares has increased by 17.05% in one year.

Current Share Class	84.47M
Shares Outstanding	84.47M
Shares Change (YoY)	+17.05%
Shares Change (QoQ)	+1.24%
Owned by Insiders (%)	4.96%
Owned by Institutions (%)	4.58%
Float	66.03M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.05
PB Ratio	1.22
P/TBV Ratio	1.40
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-14.86
EV / Sales	2.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.14

Financial Position

The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.27.

Current Ratio	2.28
Quick Ratio	1.79
Debt / Equity	0.27
Debt / EBITDA	n/a
Debt / FCF	-1.99
Interest Coverage	-12.32

Financial Efficiency

Return on equity (ROE) is -9.31% and return on invested capital (ROIC) is -6.00%.

Return on Equity (ROE)	-9.31%
Return on Assets (ROA)	-5.40%
Return on Invested Capital (ROIC)	-6.00%
Return on Capital Employed (ROCE)	-10.49%
Revenue Per Employee	449.17M
Profits Per Employee	-62.88M
Employee Count	147
Asset Turnover	0.40
Inventory Turnover	12.40

Taxes

Income Tax	-1.76B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.00% in the last 52 weeks. The beta is 0.12, so HLB bioStep's price volatility has been lower than the market average.

Beta (5Y)	0.12
52-Week Price Change	-20.00%
50-Day Moving Average	1,334.86
200-Day Moving Average	1,664.78
Relative Strength Index (RSI)	69.04
Average Volume (20 Days)	2,624,132

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, HLB bioStep had revenue of KRW 66.03 billion and -9.24 billion in losses. Loss per share was -103.30.

Revenue	66.03B
Gross Profit	47.59B
Operating Income	-14.19B
Pretax Income	-12.47B
Net Income	-9.24B
EBITDA	-9.30B
EBIT	-14.19B
Loss Per Share	-103.30

Balance Sheet

The company has 32.03 billion in cash and 29.88 billion in debt, giving a net cash position of 2.15 billion or 25.43 per share.

Cash & Cash Equivalents	32.03B
Total Debt	29.88B
Net Cash	2.15B
Net Cash Per Share	25.43
Equity (Book Value)	110.86B
Book Value Per Share	1,259.68
Working Capital	28.80B

Cash Flow

In the last 12 months, operating cash flow was -13.98 billion and capital expenditures -1.06 billion, giving a free cash flow of -15.04 billion.

Operating Cash Flow	-13.98B
Capital Expenditures	-1.06B
Free Cash Flow	-15.04B
FCF Per Share	-178.02

Margins

Gross margin is 72.07%, with operating and profit margins of -21.49% and -14.00%.

Gross Margin	72.07%
Operating Margin	-21.49%
Pretax Margin	-18.89%
Profit Margin	-14.00%
EBITDA Margin	-14.09%
EBIT Margin	-21.49%
FCF Margin	n/a

Dividends & Yields

HLB bioStep does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.05%
Shareholder Yield	-17.05%
Earnings Yield	-6.84%
FCF Yield	-11.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 31, 2022. It was a forward split with a ratio of 9.

Last Split Date	May 31, 2022
Split Type	Forward
Split Ratio	9

Scores

HLB bioStep has an Altman Z-Score of 2.79 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.79
Piotroski F-Score	3